MOPC-315 murine plasmacytoma as a model anticancer screen for human multiple myeloma
Related Experiment Videos
Abstract:
The murine tumor MOPC-315 plasmacytoma was studied as a model for human multiple myeloma. Plasmacytoma cells (10(6)) were injected iv into BALB/c mice, and 14 days later a single ip dose of the anticancer agent to be tested was administered at a dose that would result in 10% toxicity within 30 days (LD10). Increases in life-span and cures resulting from the LD10 dose were the parameters assessed. The response of this MOPC-315 plasmacytoma model to a variety of anticancer agents demonstrated good correlation with clinically active agents. A number of investigational agents were found to be highly active and potential candidates for clinical phase II studies.
Insights
This study validated the MOPC-315 plasmacytoma in mice as a model for multiple myeloma. The model effectively predicted the efficacy of anticancer agents in clinical trials.
Area of Science:
- Oncology
- Pharmacology
- Animal Models
Background:
- Multiple myeloma is a hematologic malignancy with limited treatment options.
- Developing reliable preclinical models is crucial for identifying effective therapies.
Purpose of the Study:
- To evaluate the MOPC-315 plasmacytoma in BALB/c mice as a preclinical model for human multiple myeloma.
- To assess the efficacy of various anticancer agents using this murine model.
Main Methods:
- MOPC-315 plasmacytoma cells were inoculated intravenously into BALB/c mice.
- Anticancer agents were administered at a dose causing 10% toxicity (LD10).
- Efficacy was measured by increases in lifespan and cure rates.
Main Results:
- The MOPC-315 plasmacytoma model showed a strong correlation between its response to agents and their known clinical activity.
- Several investigational agents demonstrated significant anti-tumor activity in this model.
Conclusions:
- The MOPC-315 plasmacytoma is a valuable and predictive preclinical model for multiple myeloma drug discovery.
- This model can aid in selecting promising agents for clinical trials.